Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens tech aims to sharpen sight after cataracts

NCT ID NCT07484191

Symptom relief Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study tests new versions of Clareon Vivity Pro intraocular lenses (IOLs) to see if they improve vision better than current lenses. About 231 adults with cataracts in both eyes will receive one new lens and one current lens to compare results. The main goal is to measure how well participants see at arm's length (66 cm) in bright light.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

165 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Cataracts in both eyes. * Preoperative corneal astigmatism of less than 1.00 diopter (D) in each eye. * Potential postoperative best corrected visual acuity (BCDVA) of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Desires monovision correction. * Predicted post-operative residual astigmatism of more than 1D in either eye. * Any ocular or systemic co-morbidity that, in the investigator's medical opinion, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject. * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aphakia cataract congenital primary aphakia presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia Presbyopia

Contacts and locations

Locations

  • Eye Surgery Associates - East Melbourne

    East Melbourne, Victoria, 3002, Australia

  • Focus Vision

    Woolloongabba, Queensland, 4102, Australia

  • Peninsula Eye Center

    Mornington, Victoria, 3931, Australia

  • Personaleyes Parramatta

    Sydney, New South Wales, 2150, Australia

  • Vision Eye Institute - Chatswood

    Sydney, New South Wales, 2067, Australia

  • Wollongong Eye Specialists

    Wollongong, New South Wales, 2500, Australia

  • iVision Clinic

    Campsie, New South Wales, 2194, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.